Back

Maternal and fetal outcomes of various lipid-lowering treatment regimens during pregnancy: insights from the czech national registry 2012-2023

29 August 2025 (07:00 - 18:00)
Organised by: Logo
Congress Presentation Part of: Sex differences (1) Epidemiology ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Mrs Pavla Jadrnickova

Faculty of Medicine of the University of Ostrava, Ostrava (Czechia)

5 More presentations in this session

Presentation thumbnail
Gender affects care and prognosis in acute coronary syndrome
Doctor C. Sari (Budapest, HU)
Abstract Slides Video
Presentation thumbnail
Distinctions in cell biosynthesis and fuel oxidation between sexes are linked to better left ventricular global longitudinal strain in older women.
Doctor M. Aw (Singapore, SG)
Abstract Slides Video
Presentation thumbnail
Pro-atherogenic monocytes as risk prediction marker for severe coronary artery disease in post-menopausal women
Mrs J. Kielb (Duesseldorf, DE)
Abstract Slides Video
Presentation thumbnail
Sex differences in physical activity trajectories and risks for adverse outcomes in patients with implantable cardioverter defibrillators
Doctor A. Gaffey (New Haven, US)
Abstract Slides Video
Presentation thumbnail
Sex-specific association of coagulation factor XI with 2-year cardiovascular outcomes in multivessel coronary artery disease: insights into a paradoxical cardioprotective role
Miss K. Zhang (Beijing, CN)
Abstract Slides Video

Access the full session

Session thumbnail
Sex differences (1)

The Event

Event poster

ESC Congress 2025

29 August - 1 September 2025
You may be interested in
thumbnail
Congress Presentation
Risks of antihypertensive treatment use in different periods of pregnancy
thumbnail
Congress Presentation
ACE inhibitor and angiotensin receptor blocker use during pregnancy: data from the ESC Registry of pregnancy and cardiac disease (ROPAC)
thumbnail
Congress Presentation
Pregnancy protection in women of child-bearing age prescribed ACE inhibitors, ARBs or statins - A nationwide cohort study

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources